Infectious Diseases News and Research

RSS

NIH awards $9 million grant to study aging and immunity to infections

The Trudeau Institute today announced that faculty member Laura Haynes, Ph.D., was awarded a grant from the National Institutes of Health (NIH) to study how aging impacts the immune system's response to influenza infection and vaccination.

15 Jun 2012

Breast milk protects against oral transmission of HIV

More than 15 percent of new HIV infections occur in children. Without treatment, only 65 percent of HIV-infected children will live until their first birthday, and fewer than half will make it to the age of two. Although breastfeeding is attributed to a significant number of these infections, most breastfed infants are not infected with HIV, despite prolonged and repeated exposure.

15 Jun 2012

Tooth scaling reduces CV disease risk

Taiwanese study results show that undergoing tooth scaling significantly reduces the risk for future myocardial infarction, stroke, and total cardiovascular events.

14 Jun 2012

First inventory of microbial diversity in the world's oceans

The landmark publication this week of a "map" of the bacterial make-up of healthy humans has deep roots in an unexpected place: the ocean.

14 Jun 2012

Researchers identify primary player of the biochemical bugle call

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

14 Jun 2012

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Today, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children's National Medical Center, began vaccinating participants for a Phase 1 clinical trial of a novel human hookworm vaccine.

14 Jun 2012

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Inovio Pharmaceuticals, Inc. announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.

14 Jun 2012

MDA5 molecule plays a critical role in fighting viral infections

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

HLA B-27 protein appears to confer ability to suppress HIV viral replication

The rare ability of some individuals to control HIV infection with their immune system alone appears to depend - at least partially - on specific qualities of the immune system's killer T cells and not on how many of those cells are produced.

13 Jun 2012

Transgenic mosquitoes can control malaria

Mosquitoes bred to be unable to infect people with the malaria parasite are an attractive approach to helping curb one of the world's most pressing public health issues, according to UC Irvine scientists.

13 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

Trudeau Institute to receive sub-contract for translational research grant from NIH

The Trudeau Institute has announced it is the recipient of a sub-contract for a translational research grant from the National Institutes of Health.

12 Jun 2012

Antibacterial cloths could reduce geriatric MRSA

Using disposable antibacterial cloths to bathe elderly patients reduces the transmission rate of methicillin-resistant Staphylococcus aureus, show Canadian study results.

11 Jun 2012

Polymorphism ’protective in pneumococcal disease’

Patients with invasive pneumococcal disease who have the FcyRIIa-R/R131 polymorphism may have better survival outcomes than those without the genotype, suggest study findings.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012